In Vivo Engineering of Therapeutic Cells Summit 2023

Returning to Boston for 2023, the 2nd In Vivo Engineering of Therapeutic Cells Summit is the only industry focused meeting place future innovations in the cell and gene space front and centre - dedicating time to explore the blockbuster potential of in vivo cell engineering with a key focus on optimizing delivery, targeting and specificity.

Get caught up to speed on this dynamic industry with expertise shared from the likes of Capstan Therapeutics, Interius Biotherapeutics, Vector Biopharma and many others as the titans of industry unite to showcase the latest delivery technologies that are set to transform the cell and gene space.

Join your community of 100+ industry experts to revolutionise the future of modern medicine, bringing affordable and transformative cell therapies to patients at need globally.

URLs:
Website: https://go.evvnt.com/1635974-0?pid=10018
Brochure: https://go.evvnt.com/1635974-2?pid=10018
Tickets: https://go.evvnt.com/1635974-3?pid=10018

Prices:
Drug Developer - Conference + Workshop Day: USD 3296.00,
Drug Developer - Conference Only: USD 2099.00,
Academic - Conference + Workshop Day: USD 2596.00,
Academic - Conference Only: USD 1699.00,
Service Provider - Conference + Workshop Day: USD 4296.00,
Service Provider - Conference Only: USD 2799.00

Speakers: Adi Barzel Professor, Co-Founder, Tel Aviv University, Logic Bio, Tabby Therapeutics, Adrian Bot, CSO, Capstan Therapeutics, Anna French, Partner, Qiming Venture Partners, Artavazd Arumov, VP, Qiming Venture Partners, Bakul Gupta CEO, Co-Founder, ImmTune Therapies Limited, Cecile Bauche, Founder, CSO, Alaya Bio, Cory Sago, CEO, Stealth Mode Biotech, David Johnson, CEO, GigaMune, David Peritt, President and Co-Founder, Lupagen, Gregory Newby, Assistant Professor, Johns Hopkins Department of Genetic Medicine, Haig Aghajanian, VP, Research Capstan Therapeutics, Jagesh Shah, VP, Gene Therapy, Sana Biotechnology, James Edinger, Senior VP, Preclinical Science, Mustang Bio, Lorenz Mayr, CEO, Vector BioPharma, Mary Haak-Frendscho, CEO, Spotlight Therapeutics, Mary Janatpour, EVP and CSO, Spotlight Therapeutics, Owen Fenton, Assistant Professor, University of North Carolina, Phil Johnson, President and CEO, Interius BioTherapeutics, Renaud Vaillant, President and Co-Founder, Alaya Bio, Sheena Smith, Head of Program Management, Vector BioPharma